Structure Therapeutics Inc

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Structure Therapeutics, Inc. is a clinical stage global biopharmaceutical company, which engages in developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. The company was founded by Raymond Stevens in February 2019 and is headquartered in South San Francisco, CA.

12-week Phase 2a and Phase 1b multiple ascending dose (MAD) topline results  expected to be announced in latter half of fourth quarter 2023

Structure Therapeutics Initiates Phase 2a Study of Oral GLP-1 agonist GSBR-1290 for the Treatment of Type 2 Diabetes and Obesity

Posters include data across biomarker, translation and clinical studies supporting development of cardiopulmonary programs LTSE-2578 and ANPA-0073 Posters include data across biomarker, translation and clinical studies supporting development of cardiopulmonary programs LTSE-2578 and ANPA-0073

Structure Therapeutics Announces Poster Presentations at the American Thoracic Society International Conference

Oral GLP-1 agonist GSBR-1290 advancing into Phase 2a study in type 2 diabetes and obesity Topline data from Phase 1b multiple ascending dose and Phase 2a studies of GSBR-1290 expected in second half 2023 SAN FRANCISCO and SHANGHAI, May 11, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and pulmonary diseases, today reported financial results for the first quarter ended March 31, 2023, and highlighted recent corporate achievements. “We are rapidly advancing GSBR-1290, our lead program in our oral GLP-1 franchise,” said Raymond Stevens, Ph.D.

Structure Therapeutics Reports First Quarter 2023 Financial Results and Recent Highlights

Structure Therapeutics has a promising pipeline of product candidates, including GSBR-1290, a GLP-1R agonist for diabetes and obesity, and APJR and LPA1R agonists and antagonists for various indications. The company has several competitive advantages, including its proprietary platform, strong IP portfolio, and experienced management team.

Structure Therapeutics: Developing Innovative Treatments For Metabolic And Fibrotic Diseases

Completed dosing of Phase 1b study of oral GLP-1 agonist GSBR-1290 Topline data from Phase 1b and Phase 2a studies of GSBR-1290 expected in 2H 2023 Completed $185.3 million upsized initial public offering

Structure Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights

SAN FRANCISCO and SHANGHAI, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and pulmonary diseases, today announced the closing of its previously announced upsized initial public offering of 12,351,000 American depositary shares (ADSs), each representing three ordinary shares, including the full exercise of the underwriters' option to purchase up to 1,611,000 additional ADSs, at a public offering price of $15.00 per ADS. The aggregate gross proceeds to Structure Therapeutics from the offering were approximately $185.3 million before deducting underwriting discounts and commissions and offering expenses. All of the ADSs were offered by Structure Therapeutics. The shares began trading on the Nasdaq Global Market on February 3, 2023 under the ticker symbol “GPCR.”

Structure Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional American Depositary Shares

Structure Therapeutics Inc. GPCR, priced 10.74 million American depositary shares at $15 each to raise $161 million in its initial public offering with joint book-running managers Jefferies, SVB Securities, Guggenheim Securities, and BMO Capital Markets. The IPO from the California-based biopharmaceutical company that's developing oral therapeutics priced at the top end of its estimated price range of $13 to $15 a share.

Structure Therapeutics IPO prices at top of range with larger number of shares added in a sign of healthy investor interest

This article was produced and syndicated by Wealth of Geeks.

Drug Maker Structure Therapeutics Offers Big Bet on ‘Diabesity' With IPO

SAN FRANCISCO and SHANGHAI, China, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and pulmonary diseases, today announced the pricing of its upsized initial public offering of 10,740,000 American depositary shares (ADSs), each representing three ordinary shares, at a public offering price of $15.00 per ADS. The aggregate gross proceeds to Structure Therapeutics from the offering are expected to be $161.1 million before deducting underwriting discounts and commissions and offering expenses. In addition, Structure Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 1,611,000 ADSs at the initial public offering price, less underwriting discounts and commissions. All of the ADSs are being offered by Structure Therapeutics. The shares are expected to begin trading on the Nasdaq Global Market on February 3, 2023 under the ticker symbol “GPCR.” The offering is expected to close on February 7, 2023, subject to the satisfaction of customary closing conditions.

Structure Therapeutics Announces Pricing of Upsized Initial Public Offering

Structure Therapeutics could raise up to $135 million in its IPO set to make its trading debut this week. The company is hoping to impress investors with its cutting-edge drugs, strong executive team and bi-continental China-U.S. organization.

Structure Therapeutics Hopes To Wow Investors With Cutting-Edge Drug Tech

Structure Therapeutics has filed proposed terms for a $125 million IPO. The firm is developing treatments for Type 2 diabetes and other serious chronic diseases.

IPO Update: Structure Therapeutics Readies $125 Million IPO

Structure Therapeutics Inc. has set terms for its initial public offering (IPO), as the California-based biopharmaceutical company developing oral therapeutics looks to raise up to $134.25 million. The company is offering 8.95 million American depositary shares (ADS), representing 26.85 million ordinary shares, in the IPO, which is expected to price between $13 and $15 per ADS.

Structure Therapeutics sets IPO terms, to be valued at up to $522 million

Structure Therapeutics has filed to raise $119 million in a U.S. IPO, although the final figure may differ. The firm is developing treatments for Type 2 diabetes and other serious medical conditions.

Structure Therapeutics Starts U.S. IPO Plan

News for Structure Therapeutics Inc Stock (GPCR)